SCHEMBL561869

SCHEMBL561869

O=C(OCCBr)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.70
LMNA P02545 2/20 0.66
MAPK1 P28482 1/20 0.57
HIF1A Q16665 1/20 0.57
SLC6A2 P23975 1/20 0.57
SLC6A3 Q01959 1/20 0.57
KMT2A Q03164 1/20 0.57
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
F2 P00734 1/20 0.52
TSHR P16473 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 1/20 0.51
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28137170 0.98 TDP1 (0.68) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL28488838 0.89 TDP1 (0.54) TDP1LMNAMAPK1SLC6A2SLC6A3
SCHEMBL4111265 0.88 TDP1 (0.85) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL3025063 0.88 TDP1 (0.78) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL137486 0.87 TDP1 (0.83) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL27765449 0.86 TDP1 (0.81) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL4230132 0.86 TDP1 (0.81) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL14673017 0.86 TDP1 (0.81) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL1656434 0.86 TDP1 (0.81) TDP1LMNAMAPK1HIF1ASLC6A2
SCHEMBL537205 0.85 TDP1 (0.65) TDP1LMNAMAPK1HIF1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-26 US disclosed
WO-2025262596-A1 METHODS OF MAKING OSIVELOTOR PFIZER INC. (US) 2025-12-26 WO disclosed
US-12370263-B2 Cyclic dinucleotide derivative based antibody-drug conjugates DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-07-29 US disclosed
CN-115209921-B Antibody drug conjugates comprising cyclic dinucleotide derivatives 第一三共株式会社 2025-06-24 CN disclosed
EP-4524154-A2 ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2025-03-19 EP disclosed
EP-3848054-B1 ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2025-01-29 EP disclosed
CN-119291192-A Kit for detecting content of fentanyl and analogues thereof and application of kit 中国药科大学 2025-01-10 CN disclosed
US-20240293567-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-09-05 US disclosed
CN-112839942-B 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社 钟根堂 2024-08-23 CN disclosed
CN-112714649-B Cyclic dinucleotide derivatives and antibody drug conjugates thereof 第一三共株式会社 2024-07-02 CN disclosed
US-4366153-A CEPHALOSPORINS; ANTIBIOTICS; BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-12-28 US disclosed
US-4341775-A CEPHALOSPORINS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-07-27 US disclosed
EP-0049539-A1 Thiazole derivatives for preparing cephem compounds and processes for their preparation FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-04-14 EP disclosed
US-4304921-A Method of preparing β-halo esters from cyclic acetals VANDERBILT UNIVERSITY (US) 1981-12-08 US disclosed
US-4304770-A Syn-isomer of 3,7-disubstituted-3-cephem-4-carboxylic acid compounds and processes for the preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4284631-A 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US disclosed
US-4220761-A 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-09-02 US disclosed
EP-0007633-A2 Cephem compounds, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-02-06 EP disclosed
US-4139620-A HYPOTENSIVE AGENTS A. H. ROBINS COMPANY, INC. (US) 1979-02-13 US disclosed
US-4096331-A HYPOTENSIVE A. H. ROBINS COMPANY, INCORPORATED (US) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12370263-B2 Cyclic dinucleotide derivative based antibody-drug conjugates STING1, CGAS, CDA TDP1 722/4885LMNA 3033/4885MAPK1 3057/4885
US-20240293567-A1 NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF STING1, CGAS, TLR9 TDP1 733/4885LMNA 2445/4885MAPK1 3100/4885
US-12637451-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX1, P2RX7 TDP1 2656/4885LMNA 1772/4885MAPK1 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.